Ligand spin-out spies share of growing antibody discovery market

24 March 2022
lab_beaker_research_biotech_big

In the latest in  a series of life sciences SPAC mergers, Ligand Pharmaceuticals (Nasdaq: LGND) is to use the approach to hive off its antibody business.

The company’s antibody discovery biotech, OmniAb, will be spun-out and then immediately merged with a newly-formed subsidiary of Avista Public Acquisition Corp II (APAC), a blank check company.

APAC, a private equity firm focused on the healthcare industry, will invest up to $115 million in the combined company, whereas Ligand will contribute $15 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology